Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: January 28, 2014
Last updated: May 4, 2016
Last verified: May 2016
Patients with severe thalassemia (thalassemia major) present with severe anemia that requires life-long transfusion therapy, spleen enlargement that may lead to increased transfusion requirement, and other serious complications as early death, growth retardation, bone deformations and iron overload due to blood transfusions. Splenectomy can significantly reduce transfusion requirement in thalassemia patients, but it is associated with an increased risk of serious complications such as sepsis and thrombosis. Preliminary preclinical and clinical data suggest that JAK2 inhibition, by reducing spleen size, may improve hemoglobin levels, thereby eliminating the need for splenectomy and reducing transfusion requirement and related iron overload.

Condition Intervention Phase
Thalassemia Major
Drug: INC424 (ruxolitinib)
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single Arm, Multicenter, Phase IIa Study to Explore the Efficacy and Safety of Ruxolitinib (INC424) in Regularly Transfused Patients With Thalassemia

Resource links provided by NLM:

Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Percent change of RBC (Red Blood Cell) transfusion requirement [ Time Frame: week 6 to week 30 ]
    Percent change in RBC transfusion requirement between week 6 and week 30 and the baseline period between week -24 and the day before first study drug administration.

Secondary Outcome Measures:
  • Change of spleen volume [ Time Frame: baseline, week 12, week 30 ]
    Change of spleen volume from baseline measured by MRI or CT at week 12 and week 30

  • Change of pre-transfusion hemoglobin level [ Time Frame: baseline, week 1,2,3,4,6,12,18,24,30 ]
    Change of pre-transfusion hemoglobin level from baseline at each post-baseline visit

  • Change of spleen length [ Time Frame: baseline, week 1,2,3,4,6,12,18,24,30 ]
    Change of spleen length from baseline over time measured by palpation

  • Pharmacokinetics (PK) parameters of Cmin and C max [ Time Frame: baseline, week 2, 12 ]
    C min and C max (1h) of INC424 by actual dose administered

  • Number of participants with adverse events as a measure of safety and tolerability [ Time Frame: baseline, week 1,2,3,4,6,12,18,24,30 ]
    Adverse events (AEs), serious adverse events (SAEs), lab results, ECGs, vital signs

Enrollment: 30
Study Start Date: May 2014
Study Completion Date: April 2016
Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Study Treatment
Approximately thirty regularly transfused adult patients with thalassemia and spleen enlargement.
Drug: INC424 (ruxolitinib)
INC424 oral tablet (5 miligrams)


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients 18 years of age or older
  2. Patients with thalassemia on a regular and stable transfusion regimen (at least 2 RBC units within every 4-week interval for 24 weeks prior to Screening) and anticipated to receive the same transfusion regimen during the study.
  3. Patients with spleen enlargement at Screening, defined as spleen palpable below the costal margin and spleen volume of ≥ 450 cm3 as confirmed by MRI (or CT scan in applicable patients).
  4. Patients need to be on iron chelation treatment (deferoxamine or deferasirox) for at least four weeks prior to Screening

Exclusion Criteria:

  1. Splenectomy prior to or planned during the study.
  2. Active serious bacterial, mycobacterial, fungal, parasitic or viral infection which requires therapy (e.g., pneumonia, tuberculosis, systemic mycosis, herpes zoster).
  3. Hemoglobin <65 g/L (<4.0 mmol/L) at Screening.
  4. Platelet count <75×109/L, absolute neutrophils count < 1.5×109/L at Screening.
  5. Estimated MDRD < 30 mL/min/1.73 m2 at Screening.
  6. ALT (SGPT) levels >5 times ULN at Screening.
  7. Hepatocellular disease such as hepatitis B (presence of HBs antigen), hepatitis C (presence of HCV RNA), liver cirrhosis.
  8. HIV positivity

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02049450

Novartis Investigative Site
Athens, GR, Greece, GR-115 27
Novartis Investigative Site
Milano, MI, Italy, 20122
Novartis Investigative Site
Palermo, PA, Italy, 90146
Novartis Investigative Site
Beirut, Lebanon, 1107 2020
Novartis Investigative Site
Bangkok, Thailand, 10700
Novartis Investigative Site
Istanbul, Turkey, 34093
Novartis Investigative Site
Izmir, Turkey, 35040
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals Identifier: NCT02049450     History of Changes
Other Study ID Numbers: CINC424X2201
Study First Received: January 28, 2014
Last Updated: May 4, 2016

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
thalassemia, spleen enlargement

Additional relevant MeSH terms:
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn processed this record on May 25, 2017